Panel: Obesity and Cardiometabolic Drug Development Beyond GLP-1

Session details:

The obesity wave is evolving quickly from single agents to combinations, oral options, and multi-receptor agonists. This panel looks at differentiation, durability, safety, and trial design in an increasingly crowded landscape. 
 
Key discussion points: 

• Oral GLP-1s and what they change for adherence and access
• Multi-agonists and combinations: GLP-1 plus glucagon, GIP, amylin and beyond
• New mechanisms beyond incretins
• New mechanisms beyond incretins
• Cardiorenal outcomes, lean mass preservation, less frequent dosing, and long-term safety
• Lifecycle strategy: comorbidities, MASH, HFpEF, and prevention